Related references
Note: Only part of the references are listed.A robust Bayesian meta-analytic approach to incorporate animal data into phase I oncology trials
Haiyan Zheng et al.
STATISTICAL METHODS IN MEDICAL RESEARCH (2020)
Variance prior specification for a basket trial design using Bayesian hierarchical modeling
Kristen M. Cunanan et al.
CLINICAL TRIALS (2019)
Definitions and statistical properties of master protocols for personalized medicine in oncology
Lindsay A. Renfro et al.
JOURNAL OF BIOPHARMACEUTICAL STATISTICS (2018)
A Bayesian basket trial design using a calibrated Bayesian hierarchical model
Yiyi Chu et al.
CLINICAL TRIALS (2018)
Bayesian basket trial design with exchangeability monitoring
Brian P. Hobbs et al.
STATISTICS IN MEDICINE (2018)
HER kinase inhibition in patients with HER2-and HER3-mutant cancers
David M. Hyman et al.
NATURE (2018)
Statistical controversies in clinical research: basket trials, umbrella trials, and other master protocols: a review and examples
L. A. Renfro et al.
ANNALS OF ONCOLOGY (2017)
Master Protocols to Study Multiple Therapies, Multiple Diseases, or Both
Janet Woodcock et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Increasing the efficiency of oncology basket trials using a Bayesian approach
Rong Liu et al.
CONTEMPORARY CLINICAL TRIALS (2017)
Addressing potential prior-data conflict when using informative priors in proof-of-concept studies
Timothy Mutsvari et al.
PHARMACEUTICAL STATISTICS (2016)
Robust exchangeability designs for early phase clinical trials with multiple strata
Beat Neuenschwander et al.
PHARMACEUTICAL STATISTICS (2016)
RECIST 1.1-Update and clarification: From the RECIST committee
Lawrence H. Schwartz et al.
EUROPEAN JOURNAL OF CANCER (2016)
The Bayesian basket design for genomic variant-driven phase II trials
Richard Simon et al.
SEMINARS IN ONCOLOGY (2016)
Time for one-person trials
Nicholas J. Schork
NATURE (2015)
Vemurafenib in Multiple Nonmelanoma Cancers with BRAF V600 Mutations
David M. Hyman et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Bayesian hierarchical modeling of patient subpopulations: Efficient designs of Phase II oncology clinical trials
Scott M. Berry et al.
CLINICAL TRIALS (2013)
Adaptive adjustment of the randomization ratio using historical control data
Brian P. Hobbs et al.
CLINICAL TRIALS (2013)
Preparing for Precision Medicine
Reza Mirnezami et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Commensurate Priors for Incorporating Historical Information in Clinical Trials Using General and Generalized Linear Models
Brian P. Hobbs et al.
BAYESIAN ANALYSIS (2012)
Hierarchical Commensurate and Power Prior Models for Adaptive Incorporation of Historical Information in Clinical Trials
Brian P. Hobbs et al.
BIOMETRICS (2011)
New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
E. A. Eisenhauer et al.
EUROPEAN JOURNAL OF CANCER (2009)
Bayesian designs to account for patient heterogeneity in phase II clinical trials
Peter F. Thall et al.
CURRENT OPINION IN ONCOLOGY (2008)
Methods of joint evaluation of efficacy and toxicity in phase II clinical trials
Caroline Tournoux et al.
CONTEMPORARY CLINICAL TRIALS (2007)
Hierarchical Bayesian approaches to phase II trials in diseases with multiple subtypes
PF Thall et al.
STATISTICS IN MEDICINE (2003)